Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acrivon Therapeutics Inc. Common Stock
NASDAQ ACRV
Data sourced from
and
and
Acrivon Therapeutics Inc. Common Stock Current Liabilities to Total Liabilities Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024
Acrivon Therapeutics Inc. Common Stock Current Liabilities to Total Liabilities Ratio 3 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The current liabilities to total liabilities ratio measures the proportion of a company's current liabilities in relation to its total liabilities. It is calculated by dividing current liabilities by total liabilities. This ratio provides insights into the percentage of a company's total liabilities that are classified as current liabilities. It helps evaluate the company's overall liability structure and the importance of short-term obligations in relation to total liabilities. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Acrivon Therapeutics Inc. Common Stock Current Liabilities to Total Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.32, a 1,322.92% change year over year.
-
Acrivon Therapeutics Inc. Common Stock Current Liabilities to Total Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.02.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ACRV
| CEO | Dr. Peter Blume-Jensen M.D., Ph.D. |
| IPO Date | Nov. 15, 2022 |
| Location | United States |
| Headquarters | 480 Arsenal Way, Watertown, MA, United States, 02472 |
| Employees | 58 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Key trends
Similar companies
Aerovate Therapeutics Inc
NA
NA
Adagene Inc
NA
NA
AN2 Therapeutics Inc
NA
NA
Anebulo Pharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email